

Overexpression of mitochondrial oxodicarboxylate carrier (ODC1) preserves oxidative phosphorylation in a yeast model of the Barth Syndrome

Maxence de Taffin de Tilques^{1\$}, Déborah Tribouillard-Tanvier^{1\$ #}, Emmanuel Tétaud¹, Eric Testet², Jean-Paul di Rago¹, and Jean-Paul Lasserre^{1*}

¹ Université de Bordeaux, Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, 1 rue Camille Saint-Saëns, 33077 Bordeaux cedex, France

² Université de Bordeaux, Laboratoire de biogenèse membranaire, CNRS UMR 5200, INRA Bordeaux Aquitaine BP81, Bordeaux, France

[#] Research associate from INSERM

^{\$} These authors equally contributed

*To whom correspondence should be addressed: tribouillard@ibgc.cnrs.fr or lasserre@ibgc.cnrs.fr

Keywords: Human mitochondrial disease, oxidative phosphorylation, Barth syndrome, oxodicarboxylic acid transport, cardiolipin remodeling, tafazzin

SUMMARY STATEMENT

Our findings make the transport of oxodicarboxylic acids (ODC1) across the mitochondrial inner membrane as a potential target for the treatment of BTHS patients and other diseases caused by mitochondrial dysfunction.

ABSTRACT

Cardiolipin (CL) is a diglycerol phospholipid mostly found in mitochondria where it optimizes numerous processes including oxidative phosphorylation (OXPHOS). To function properly CL needs to be unsaturated, which requires the acyltransferase tafazzin. Loss-of-function mutations in this protein are responsible for the Barth syndrome (BTHS), presumably because of a diminished OXPHOS capacity. Here we show that overexpressing Odc1p, a conserved oxodicarboxylic acid carrier located in the mitochondrial inner membrane, fully restores oxidative phosphorylation in a yeast model (*taz1Δ*) of the Barth syndrome. The rescuing activity involves the recovery of a normal expression of key components that sustain oxidative phosphorylation, including the cytochrome c and complexes IV and III, that are strongly down regulated in *taz1Δ* yeast. Interestingly, overexpressing Odc1p was shown previously to rescue also yeast models of mitochondrial diseases caused by defects in the assembly of ATP synthase and by mutations in the MPV17 protein that result in the hepatocerebral mitochondrial DNA depletion syndrome. These findings define the transport of oxodicarboxylic acids across the inner membrane as a potential therapeutic target for a large spectrum of mitochondrial disease including BTHS.

INTRODUCTION

Cardiolipin (CL) is an acidic diglycerophospholipid carrying two negative charges that is exclusively synthesized in mitochondria and mostly found in the mitochondrial inner membrane (IM) (Hostetler et al., 1972; Bligny and Douce, 1980; Hoch, 1992; Schlame and Haldar, 1993; Schlame et al., 2000; Joshi et al., 2009; Ikon et al., 2015). CL has a structure more flexible than other phospholipids because of two chiral carbons and four fatty acyl chains usually polyunsaturated. CL facilitates cristae formation (Xu et al., 2006; Acehan et al., 2011; Schlame et al., 2012) and establishes interactions with electron transport chain components (complexes I-IV) promoting their association into 'supercomplexes' or 'respirasomes', which is presumed to optimize respiration (Zhang et al., 2002; Pfeiffer et al., 2003; Bazan et al., 2013). CL also plays a role in many others processes including mitochondrial fusion (Joshi et al., 2012), fission (DeVay et al., 2009; Ban et al., 2010), protein import (Jiang et al., 2000; Gebert et al., 2009), iron-sulfur (Fe-S) biogenesis (Patil et al., 2013), mitophagy (Chu et al., 2013, 2014; Hsu et al., 2015; Li et al., 2015) and apoptosis (McMillin and Dowhan, 2002; Kim et al., 2004; Heit et al., 2011; Gonzalvez et al., 2013; Ikon et al., 2015; Li et al., 2015; Manganelli et al., 2015). Furthermore, CL modulates the activity of various carrier proteins involved in energy metabolism including the ADP/ATP and carnitine acyl-carnitine translocases (Kadenbach et al., 1982; Noel and Pande, 1986; Robinson, 1993; Jiang et al., 2000; Schlame et al., 2000; Koshkin and Greenberg, 2000, 2002; Vaz et al., 2003; Gu et al., 2004; Brandner et al., 2005). Finally, the polyunsaturated chains of CL would provide a shield against reactive oxygen species (ROS) that have the capacity to damage any type of biomolecules (McMillin and Dowhan, 2002; Kim et al., 2004; Heit et al., 2011; Gonzalvez et al., 2013; Chu et al., 2013, 2014; Hsu et al., 2015; Ikon et al., 2015; Li et al., 2015; Manganelli et al., 2015).

Premature CL is synthesized at the matrix side of IM as a saturated phospholipid from phosphatidic acid (PA) coming from the endoplasmic reticulum (ER) (Schlame and Haldar, 1993; Schlame et al., 2000). To carry out its different functions, CL needs to be unsaturated, which involves a deacylation-reacylation cycle resulting in CL species containing mainly mono-unsaturated and di-unsaturated chains of 16–18 carbons (Schlame and Haldar, 1993; Hatch, 1998; Baile et al., 2014a). This remodeling activity is sustained by a cardiolipin-specific phospholipase (*CLP1*), which generates monolyso-CL (MLCL), and a protein called tafazzin (Bolhuis et al., 1991; Ades et al., 1993; Gedeon et al., 1995; Bione et al., 1996; Barth et al., 2004) (encoded by the nuclear gene *TAZ1*) that re-acylates MLCL (Neuwald, 1997; Testet et al., 2005; Schlame, 2013).

Loss-of-function mutations in *TAZ1* gene are responsible for the Barth syndrome (BTHS), which is an X-linked recessive disorder characterized by cardiac and skeletal myopathies, growth retardation, hypocholesterolemia, 3-methyl glutaconic aciduria and increased susceptibility to bacterial infections due to cyclic neutropenia (Barth et al., 1983). The Barth syndrome is very often fatal in childhood due to cardiac failure or sepsis and there is still no effective treatment (Barth et al., 1983; Bolhuis et al., 1991). Mitochondria from BTHS patients show multiple anomalies, including: (i) a reduced level of CL with a concurrent increase in monolysocardiolipin (MLCL) (Vreken et al., 2000; Schlame et al., 2003; Valianpour et al., 2005); (ii) abnormal ultrastructure; (iii) pleiotropic respiratory defects possibly due to impaired respirasome stability (Barth et al., 1996; McKenzie et al., 2006); (iv) increased production of ROS; (v) a reduced capacity to sustain apoptosis; and (vi) an abnormally high tendency to proliferate in cells, perhaps as a means to compensate for the compromised energy-transducing activity of tafazzin deficient mitochondria (Xu et al., 2005; Gonzalvez and Gottlieb, 2007; Dudek et al., 2013; Ferri et al., 2013; Gonzalvez et al., 2013).

Much of what we know about the Barth Syndrome comes from studies in the yeast *Saccharomyces cerevisiae*, which is a convenient system for modelling mitochondrial disease mechanisms (Baile and Claypool, 2013; Lasserre et al., 2015). Studies in this yeast have helped to define how CL is synthesized and remodeled to maintain a homogenous and highly unsaturated acyl-chain composition, and how mitochondria are influenced by defects in these processes (Claypool, 2009; Joshi et al., 2009; Baile et al., 2014b; Mileykovskaya and Dowhan, 2014). Yeast strains lacking the homolog of the human *TAZ1* gene (*taz1Δ*) showed substantial MLCL accumulation with a concurrent decrease in CL (Vaz et al., 2003; Gu et al., 2004; Testet et al., 2005; Claypool, 2009) and respired poorly when grown at elevated temperature (Schlame and Haldar, 1993; Schlame et al., 2000; Vaz et al., 2003; Gu et al., 2004; Brandner et al., 2005). These phenotypes were efficiently suppressed by expressing the human *TAZ1* gene in *taz1Δ* yeast, which provided a simple assay to test the functional consequences of mutations found in BTHS patients. Most of these mutations proved, when expressed in yeast, to affect the association of tafazzin with the IM, making it susceptible to proteolytic degradation (Claypool et al., 2006; Claypool et al., 2011).

The common respiratory growth defect observed in yeast models of mitochondrial disease provides a simple read-out to enable large-scale screens for genetic suppressors able to rescue mitochondrial dysfunction (Baile and Claypool, 2013; Lasserre et al., 2015). Even when mitochondrial dysfunction is severe enough to abolish respiratory growth, yeast offers the unique advantage that such mutants can be kept alive and propagated on fermentable substrates for the use in suppressors screens. A number of interesting findings have been reported using this approach. For example, it was found that disease-causing mt-

tRNA^{Leu}(UUR) mutations are efficiently rescued in yeast by overexpressing factors involved in mitochondrial protein synthesis, including the translation factor EF-Tu (TUFM in humans) and various (cognate and non-cognate) aminoacyl tRNA synthetase (Montanari et al., 2008; Park et al., 2008; Rorbach et al., 2008; Sasarman et al., 2008; Montanari et al., 2010). The suppressor activity of these factors was also observed in human cells carrying similar mutations and shown to be independent of their tRNA charging function indicating that the mutated mt-tRNAs recover their functionality likely owing to chaperone-like RNA-protein interactions (Francisci et al., 2011).

Other interesting studies have revealed that yeast models of human diseases caused by defects in the assembly of ATP synthase (Schwimmer et al., 2005) or mutations in MPV17 (Dallabona et al., 2010), a protein of as-yet-poorly characterized function, are rescued by the overexpression of Odc1p, which is a mitochondrial carrier transporting Krebs cycle intermediates through the IM (Fiermonte et al., 2001). Since ATP synthase and MPV17 have different, apparently non-related, functions, and owing to the existence of phenotypic similarities in yeast conferred by defects in these systems and in gene *TAZ1* (see Discussion), we wondered whether Odc1p could also, when overexpressed, compensate for a lack in CL remodeling. The results reported here show that overexpressing Odc1p fully restores oxidative phosphorylation in *taz1Δ* yeast. This finding defines the transport of oxodicarboxylic acids across the IM as a potential therapeutic target for a large spectrum of mitochondrial diseases, including BTHS.

RESULTS

Construction, growth properties, phospholipid content and genetic stability of *taz1Δ* yeast

We first constructed a *taz1Δ* strain (in W303-1A genetic background *MATa*, *leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15*), by replacing the *TAZ1* coding sequence by that of *TRP1*, which encodes a protein involved in tryptophan biosynthesis. The *taz1Δ* mutant was transformed with either the empty pRS426 plasmid (*taz1Δ* + pØ) that contains *URA3* as a yeast selection marker (Mumberg et al., 1994) or the same plasmid into which we have cloned the wild type yeast *TAZ1* gene with its own promoter (*taz1Δ* + p*TAZ1*). As a control, we transformed the parental strain with pRS426 (WT + pØ). Western blot analyses of whole cell protein extracts confirmed the absence of Taz1p (the protein encoded by *TAZ1* gene) in *taz1Δ* + pØ (Fig. 1A). This protein was more abundant in *taz1Δ* + p*TAZ1* compared to WT + pØ, because pRS426 is a high copy number plasmid.

Consistent with previous studies (Testet et al., 2005), mitochondria isolated from our *taz1Δ* strain showed a significant decrease in CL level (about 50%) compared to the wild type, had a higher content in phosphatidylinositol (PI), while phosphatidylethanolamine (PE) and phosphatidylcholine (PC) normally accumulated (Fig. 1B, upper panel). As expected also, CL fatty acid chains were less unsaturated in *taz1Δ* vs WT mitochondria, with decreased levels in oleic (C18:1) and increased amounts of stearic (C18:0) acid chains (Fig. 1B, lower panel). The *taz1Δ* mutant recovered a normal phospholipid profile upon transformation with the plasmid borne *TAZ1* gene (*taz1Δ* + p*TAZ1*) (Fig. 1B).

Our *taz1Δ* strain (*taz1Δ* + pØ) grew poorly on respiratory carbon sources (ethanol) at elevated temperatures (36°C) whereas growth on non-fermentable substrates (glucose) looked normal (Fig. 2A). The respiratory growth deficiency was suppressed by the plasmid borne *TAZ1* gene (*taz1Δ* + p*TAZ1*) (Fig. 2A). We additionally tested the growth of the strains in liquid complete synthetic medium (CSM) containing 0.5% galactose and 2% ethanol and devoid of uracil for plasmid maintenance (this is the growth medium used for the bioenergetics and biochemical investigations described below). Galactose is a fermentable substrate that does not elicit repression of mitochondrial function as glucose does. The four analyzed strains grew well in this medium at 28°C (not shown), whereas at 36°C the growth of strain *taz1Δ* + pØ was much less efficient compared to the three other strains after consumption of the galactose present in the medium (Fig. 2B), which illustrates further the failure of the mutant to properly express mitochondrial function at 36°C.

Hundreds of nuclear genes required in yeast for mitochondrial function are important for mtDNA maintenance, either directly or indirectly (Contamine and Picard, 2000). Mutations in these genes result in the production of cytoplasmic *petite* cells issued from a large (>50%) deletion (ρ^-) or totally devoid (ρ^0) of mtDNA. To know if *TAZ1* gene is important for mtDNA stability, *taz1Δ* cells grown in glucose, conditions under which functional (ρ^+) mtDNA is dispensable (except in rare *petite*-negative mutant contexts (Chen and Clark-Walker, 2000), were spread for single colonies on glucose plates with limiting amount of adenine. Due to the *ade2* mutation, ρ^+ cells form pink colonies owing to a red intermediate (AIR, AminolimidazoleRibotide) of the adenine biosynthetic pathway, while *ade2* ρ^-/ρ^0 cells form white colonies because this pigment can no longer be oxidized and remains white (Reaume and Tatum, 1949; Kim et al., 2002). *taz1Δ* yeast grown in glucose at 28°C had a relatively high tendency to produce ρ^-/ρ^0 cells (50% vs <5% for the *WT*) (Fig. 2C). Since ρ^+ *taz1Δ* yeast is respiratory competent at this temperature (Fig. 2A), it can be inferred that this mtDNA instability did not result from a failure in the expression of the energetic function of mitochondria (see Discussion). When grown in the synthetic galactose/ethanol medium at the non-permissive temperature (36°C), *taz1Δ* yeast produced much less (5-10%) *petites*, demonstrating that the mutant respiratory deficiency at elevated temperature did not result from a lack in functional mtDNA. The limited tendency of *taz1Δ* yeast to produce *petites* in these conditions is probably due to a strong counter-selection of these cells whereas in pure fermenting conditions they can grow efficiently.

Bioenergetics in *taz1Δ* yeast

The impact of the loss of *TAZ1* gene on oxidative phosphorylation was investigated using mitochondria isolated from cells grown in synthetic galactose/ethanol medium lacking uracil at 36°C. The cells were harvested when the cultures reached a density of 2-3 OD_{600nm}/ml after which the growth of the mutant (*taz1Δ* + ρ^0) became very slow compared to the *WT* (*WT* + ρ^0) and the mutant transformed with the plasmid borne *TAZ1* gene (*taz1Δ* + p*TAZ1*) (see Fig. 2B). As already mentioned above, the mutant showed in these conditions a good mtDNA stability indicating that its respiratory growth defect at 36 °C did not result from a lack in functional mtDNA.

a) Respiration. We first measured mitochondrial oxygen consumption using NADH as an electron donor, alone (basal, state 4 respiration), after further addition of ADP (state 3, phosphorylating conditions) or in the presence of the membrane proton ionophore CCCP (carbonyl cyanide m-chlorophenylhydrazone) (uncoupled respiration). Under state 4, the rate of respiration is controlled by the passive permeability to protons of the inner membrane (IM). Under state 3, it is generally accepted that most of the protons return to the matrix through

the ATP synthase and that the contribution of the passive permeability to protons of the IM to respiration is then very small. In the presence of CCCP, the maintenance of an electrical potential ($\Delta\Psi$) across the IM is impossible and respiration becomes maximal. State 4 respiration was not increased in *taz1Δ* yeast compared to the two control strains (it was even a little decreased, see Fig. 3A), indicating that absence of CL remodeling does not render the IM more leaky to protons. State 3 vs state 4 respiration was only slightly higher in the mutant (by about 10%), while mitochondria from the two *TAZ1*⁺ strains responded normally to ADP with a 50% respiration rate increase (Fig. 3A). In the presence of CCCP the mutant mitochondria respired more rapidly, but there was still an important (45%) deficit in oxygen consumption compared to the two CL-remodeling competent strains (Fig. 3A). We also measured the activity of complex IV (CIV) (cytochrome *aa*₃) using ascorbate/TMPD (N,N,N',N'-tetramethyl-pphenylenediamine) as an electron donor system in the presence of CCCP. Here also, the mutant showed a substantially (50%) reduced electron transfer activity (Fig. 3B).

b) ATP synthesis. We next measured the rate of mitochondrial ATP synthesis using NADH as a respiratory substrate, in the presence of a large excess of external ADP. In these conditions, ATP is synthesized only by complex V (CV) using the proton-motive force generated by complexes III (CIII) and IV (there is no complex I in *S. cerevisiae*). In these conditions, assuming a normal or at least sufficient functioning of the ADP/ATP translocase, the intramitochondrial pool of adenine nucleotides consists almost exclusively of ADP, which favours the phosphorylating activity of complex V. This activity was substantially reduced in the *taz1Δ* mutant by at least 50% compared with the controls, WT + pØ and *taz1Δ* + p*TAZ1* (Fig. 3C). Since state 3 respiration and ATP synthesis rates were decreased in similar proportions in the mutant, it can be inferred that the observed oxidative phosphorylation deficit mostly resulted from a slower ATP synthesis rate rather than a less efficient coupling of the mitochondrial energy transducing system.

c) Membrane potential. The consequences of a lack in CL remodeling on oxidative phosphorylation were analysed further using Rhodamine 123. This is a fluorescent cationic dye that can be used to monitor changes in the IM electrical potential ($\Delta\Psi$) in intact mitochondria (Emaus et al., 1986). Increasing $\Delta\Psi$ is followed by the uptake of the dye inside the matrix space and concomitant fluorescence quenching. In a first set of experiments (Fig. 4A), we tested the capacity of externally added ADP to consume ethanol-induced $\Delta\Psi$. Despite their 50% reduced respiratory capacity (see above), ethanol induced a large $\Delta\Psi$ variation in *taz1Δ* mitochondria, which is in agreement with previous studies showing that in these conditions the rate of respiration needs to be decreased by more than 80% to obviously affect $\Delta\Psi$ (Rak et al., 2007a ; Kucharczyk et al., 2009). Normally, small amounts of

ADP induce a transient fluorescence increase due to $\Delta\Psi$ consumption by the ATP synthase during phosphorylation of the added ADP. This was indeed observed in mitochondria from the CL-remodeling competent strains (WT + p \emptyset and *taz1 Δ* + pTAZ1), whereas *taz1 Δ* mitochondria were mostly insensitive to ADP. KCN was then added to inhibit complex IV, which, in the control mitochondria, resulted in a rapid but partial $\Delta\Psi$ collapse. The remaining potential was due to the pumping of protons by the F_O component of ATP synthase coupled to the hydrolysis by its F₁ sector of the ATP that accumulated in the mitochondrial matrix during phosphorylation of the added ADP. Indeed, the remaining $\Delta\Psi$ was lost upon addition of oligomycin. In the *taz1 Δ* mitochondria the ethanol-induced $\Delta\Psi$ was essentially collapsed in one rapid phase after KCN addition, which further reflected their limited capacity to produce ATP (Fig. 4A).

In another set of experiments (Fig. 4B) we directly tested the functionality of ATP synthase using externally added ATP, thus independently of the respiratory chain activity (Fig. 4B). The mitochondria were first energized with ethanol to remove the natural inhibitory peptide (IF1) of the F₁-ATPase. The mitochondrial membrane potential was then collapsed with KCN, and less than one minute later, thus well before IF1 rebinding (Venard et al., 2003), ATP was added. Normally, the external ATP is counter-exchanged against ADP present in the matrix by the ADP/ATP translocase, which does not require any $\Delta\Psi$, and the ATP can then be hydrolyzed by F₁ coupled to F_O-mediated proton transport out of the matrix. The ATP addition promoted in both *taz1 Δ* and control mitochondria (WT + p \emptyset and *taz1 Δ* + pTAZ1) a large and stable fluorescence quenching of the dye that was reversed upon F_O inhibition with oligomycin. These results suggest that a lack in CL-remodeling has limited, if any, impact on ATP synthase expression and functionality.

d) Assembly/stability of OXPHOS components. Blue-Native-Polacrylamide-Gel-Electrophoresis (BN-PAGE) analyses of mitochondrial proteins extracted with various concentrations of digitonin revealed that full ATP synthase complexes similarly accumulated in *taz1 Δ* and wild type mitochondria, as monomeric and dimeric units (Fig. 5A). This further supports that the activity of Taz1p is not crucial for ATP synthase expression and assembly, and association into dimers. On the contrary, the respiratory system of *taz1 Δ* yeast displayed substantial defects, with a rather severe lack in CII (Fig. 5C), CIII, CIV (Fig. 5B) and cytochrome c (Fig. 5D). In BN-gels probed with Cox2 and cytochrome *b* antibodies, most of the CIV present in *taz1 Δ* mitochondrial protein samples was, as in the WT, associated with CIII within CIII₂-CIV₂ and CIII₂-CIV₁ 'supercomplexes'. The relatively weak response to cytochrome *b* antibodies of CIII₂-CIV₂ vs CIII₂-CIV₁ is certainly due to a much better accessibility of these antibodies to CIII when the CIII dimer is associated to only one CIV. For the same reason, 'free' CIII dimer responds even better to the cytochrome *b* antibodies.

While this makes it difficult to quantify within a given mitochondrial sample the relative amounts of CIII- and CIV-containing protein complexes, comparison between samples makes sense, and it appears from Fig. 5B that CIII dimer was not more abundant in *taz1Δ* yeast compared to the *WT* strain, indicating that CL remodeling inactivation leads to similar decreases in the contents of CIII and CIV.

It can be inferred from these data, that the slow growth phenotype of the *taz1Δ* mutant on respiratory carbon sources at elevated temperature results from a lack in ATP synthesis owing to a defective expression of several components involved in the transfer of electrons to oxygen.

e) ROS production / accumulation. Defects in the mitochondrial respiratory chain often result in a higher production / accumulation of reactive oxygen species (ROS) owing to the diversion of electrons from their normal pathway to oxygen. A lack in CL remodeling is known to provoke this phenomenon (Chen et al., 2008), which we observed also in our *taz1Δ* mutant (Fig. 6).

Overexpressing Odc1p fully restores oxidative phosphorylation in *taz1Δ* mutant

To test the capacity of Odc1p, when overexpressed, to compensate for a lack in CL remodeling, we transformed the *taz1Δ* mutant with a high copy number vector in which we have cloned the gene of this protein (*ODC1*) with its own promoter (*taz1Δ* + *pODC1*). As a result, Odc1p accumulated at least 10 times more than in the untransformed mutant (Fig. 1A, arrow). Overexpressing Odc1p efficiently restored the ability of *taz1Δ* yeast to grow on respiratory substrates (Fig. 2A,B). The mitochondrial phospholipid profile of the modified yeast was mostly identical to that of *taz1Δ* cells that normally express Odc1p (Fig. 1B). It can be inferred that the rescue was not induced by the restoration of CL remodeling.

Mitochondria isolated from *taz1Δ* + *pODC1* cells grown at elevated temperature respired (Fig. 3 A,B) and produced ATP efficiently (Fig. 3C), displayed normal $\Delta\Psi$ profiles (Fig. 4A), and had CIV, CIII and cytochrome *c* contents similar to those of *WT* mitochondria (Fig. 5B,D). Furthermore, the *taz1Δ* cells showed a normal production of ROS (Fig. 6). Thus, overexpressing Odc1p fully restored oxidative phosphorylation in CL-remodelling deficient yeast cells.

Oleic acid improves respiration dependent growth of *taz1Δ* yeast

Oleic acid (OA) is known to stimulate expression of Odc1p (Tibbetts et al., 2002). Thus, if overexpressing Odc1p can compensate for a lack in CL-remodelling, we expected that this

compound should be able to do so also. To test this hypothesis, *taz1Δ* cells were spread on solid ethanol medium (YPA ethanol) and exposed to filters spotted with different amounts of OA (Fig. 7). After several days of incubation at 36°C a halo of enhanced growth appeared around the filters. Oleate did not improve growth when the medium was devoid of ethanol (YPA), which demonstrates that the halos of enhanced growth resulted from a better utilization of respiratory substrates when *taz1Δ* yeast is exposed to the fatty acid.

DISCUSSION

Consistent with previous studies using yeast as a model (Schlame and Haldar, 1993; Schlame et al., 2000; Vaz et al., 2003; Gu et al., 2004; Brandner et al., 2005), we found that a lack in CL remodeling owing to inactivation of the tafazzin encoding gene (*TAZ1*) compromises respiration in yeast cells exposed to elevated temperatures. Our biochemical and bioenergetics analyses revealed that a lack in several components (CII-IV and cytochrome c) involved in electron transfer to oxygen was possibly responsible for this instead of defects in the functioning of these systems. Thus the CL levels still present (50% vs the *WT*) seem thus to be sufficient to support the function of the respiratory enzymes that accumulate in the *taz1Δ* mutant. At apparent odds with this, in a recent study (Baile et al., 2014b), while the absence of *TAZ1* gene similarly affected oxygen consumption in yeast cells grown at 37°C, accumulation of respiratory chain complexes was not found diminished. Since this study and ours used the same host strain (W301-1A), background genetic differences are likely not responsible for this apparent discrepancy. A more likely explanation is that the two studies used very different growth conditions. In (Baile et al., 2014b), the cells were grown in rich lactate media while in our case we used complete synthetic media containing galactose and ethanol. Logically, the reduced content in electron transfer proteins we observed is probably not the primary event responsible for the impairment of respiration but rather a secondary, growth condition dependent, consequence to some other functional impairment (see below). In this respect it is to be noted that CIV expression in yeast is highly regulated, as was revealed by the study of numerous ATP synthase (CV) mutants. These mutants often poorly express CIV (Kucharczyk et al., 2010; Kucharczyk et al., 2013; Kucharczyk et al., 2009; Rak et al., 2007a; Rak et al., 2007b), presumably as a means to adjust CIV expression to the activity of CV (Soto et al., 2009). Another possible explanation for the drop in CIV in our *taz1Δ* yeast is the poor expression of cytochrome c. Indeed, the binding of cytochrome c to CIV protects the Cox2 subunit of this complex against degradation by the i-AAA protease located in the IM (Nakai et al., 1995). Testing this

hypothesis is unfortunately difficult because the combined loss of Taz1p and i-AAA is synthetic lethal (Gaspard and McMaster, 2015).

To our knowledge, it is the first time that the influence of a lack of CL remodeling on the accumulation of cytochrome *c* is tested. The reduced content of this cytochrome in the yeast tafazzin mutant is an interesting observation that further illustrates the importance of CL remodeling for preserving mitochondrial function. CL is known to be important for anchoring cytochrome *c* to the IM, which has been proposed to facilitate electron transfer from CIII to CIV (Orrenius and Zhivotovsky, 2005). It is possible that this interaction is impaired in *taz1Δ* yeast, and the released cytochrome *c* becomes more susceptible to proteolytic degradation. The high sensitivity of cytochrome *c* to oxidative damage possibly also contributes to the reduced accumulation of this protein in *taz1Δ* yeast owing to its enhanced propensity to produce ROS (Chen et al., 2008, this study). It will be of interest to determine whether a lack in cytochrome *c* contributes to the decreased rate of respiration in human CL remodeling deficient cells.

It has been established that CL is important for the association of respiratory complexes into supramolecular structures called respirasomes, and this organization is supposed to optimize respiration and minimize ROS production (Zhang et al., 2002; Pfeiffer et al., 2003; Claypool et al., 2008). There is evidence that respirasome destabilization occurs in BTHS patients, and this might contribute to the disease process (Barth et al., 1996; McKenzie et al., 2006; Gonzalez et al., 2013). While a block in CL synthesis disrupts the interactions between CIII and CIV in yeast (Baile et al., 2014b), these complexes efficiently associated into supercomplexes in *taz1Δ* yeast (Baile et al., 2014b). This indicates that the remaining CL levels (50% vs *WT*) in *taz1Δ* yeast are sufficient for making contacts between CIII and CIV, and that the compromised ability of the yeast tafazzin mutant to transfer electrons to oxygen does not result from a less efficient association of these complexes. It is to be noted here that while the yeast and human mitochondrial energy-transducing systems are generally believed as being highly similar there are some important differences like the absence of CI in yeast, which could explain at least in part why the supra-molecular structure of this system is apparently more sensitive to a lack in CL remodeling in humans than in yeast. The compromised ability of BTHS patients to express CII possibly contributes to the disorganization of the electron transport chain owing to the well-known interactions between CI and CII (Wittig and Schagger, 2009).

While *taz1Δ* cells grew well in ethanol media at 28°C (the optimal temperature for growing *S. cerevisiae*), they exhibited a somewhat high tendency to lose mtDNA when allowed to proliferate by fermentation (in glucose), i.e. under conditions where the presence of this DNA

is not essential (Fig. 2C). This result indicates that the absence of CL remodeling is not without any effect on yeast mitochondria at this temperature. A reasonable explanation is that the import into mitochondria of the systems involved in mtDNA maintenance becomes less efficient. In support to this hypothesis, it has been shown that the biogenesis of the protein translocase (TOM) and sorting and assembly (SAM) machineries of the outer mitochondrial membrane is less efficient in CL remodeling deficient yeast cells grown at 28°C, and defects in these systems are synthetic lethal with mutations in the CL-remodeling pathway (Gebert et al., 2009; Sauerwald et al., 2015). The compromised ability of the *taz1Δ* mitochondria to energize the IM (Fig. 4) could additionally impact protein import through the $\Delta\Psi$ -dependent TIM23 machinery of the IM. Studies of other yeast mutants have shown that the systems involved in mtDNA maintenance are particularly sensitive to defects in mitochondrial protein import (Lefebvre-Legendre et al., 2003). The present study underscores the importance of CL maturation for efficient mitochondrial genome propagation.

Remarkably, oxidative phosphorylation and respiratory growth could be fully restored in *taz1Δ* yeast upon artificial overexpression of Odc1p, which is a protein that transports various Krebs cycle intermediates, preferentially α -ketoglutarate, across the inner mitochondrial membrane (Fiermonte et al., 2001). The level of Odc1p in *taz1Δ* yeast was not decreased compare to the *WT* strain (Fig. 1A), indicating that the respiratory deficiency of the mutant does not result from a failure to normally express/accumulate Odc1p. It is possible that the activity of Odc1p is affected by a lack in CL remodeling, in which case its overexpression would be beneficial not by stimulating but by preserving Odc1p function. While Odc1p expression can be modulated physiologically, with a 2/3-fold increase when yeast cells are switched from fermenting to respiratory conditions (Tibbetts et al., 2002), the levels of Odc1p in the mutant transformed with a plasmid-borne *ODC1* gene were by far much, at least 10-fold, higher (Fig. 1A). Thus, yeast cells have not the physiological capacity to increase the level of Odc1p in response to a lack in CL remodeling to a level sufficient to preserve oxidative phosphorylation. This can be achieved only artificially by way of genetic or pharmacological suppressors, which is an interesting finding that could help developing therapeutic approaches against the Barth syndrome.

Increasing the levels of Odc1p was previously shown to restore also respiration-dependent growth of a yeast mutant lacking a protein (Fmc1p) involved in the assembly of the F_1 catalytic sector of CV at elevated temperatures (Lefebvre-Legendre et al., 2003; Schwimmer et al., 2005). Both complexes III and IV are strongly down regulated in this mutant. While CV assembly remained defective in *fmc1Δ* yeast when Odc1p was overexpressed, CIII and CIV recovered a much better expression (Lefebvre-Legendre et al., 2003; Schwimmer et al.,

2005). As a result, the lack in CV was compensated for by an enhanced production of ATP by substrate-level phosphorylation directly coupled to the Krebs cycle (Schwimmer et al., 2005). As in the *fmc1Δ* mutant, increasing Odc1p accumulation restored a normal expression and activity of the electron transport chain in *taz1Δ* yeast. As a result, owing to the good expression of CV in this mutant, ATP was produced again effectively through oxidative phosphorylation. Interestingly, Odc1p proved also, when overexpressed, to improve respiratory growth at elevated temperature of yeast cells lacking the gene (*SYM1*) encoding the homolog of human MVP17 (Dallabona et al., 2010). This is an IM protein of as-yet-unknown function in which mutations have been associated with the hepatocerebral form of mitochondrial DNA depletion syndrome (Spinazzola et al., 2006). Whether the rescue of *sym1Δ* yeast on respiratory substrates correlates with an improved expression/activity of the respiratory system is presently unknown.

How Odc1p, when overexpressed, compensates for defects in the oxidative phosphorylation system is certainly a complex process. Considering (i) the well-established function of this protein in the transport of α -ketoglutarate across the IM (Fiermonte et al., 2001), (ii) the kinetic control this transport exerts on oxidative phosphorylation (Rigoulet et al., 1985), and (iii) studies showing that some Krebs cycle enzymes like aconitase (Patil et al., 2013) and CII ((Dudek et al., 2016), this study) are impaired in CL remodelling deficient cells, we hypothesize that the rescuing activity of Odc1p possibly results from a better operation of the Krebs cycle. Some data reported in this study support the view that the respiratory deficiency of CL remodeling deficient cells does well involve defects in this metabolic pathway: Indeed, while ATP synthesis rate was reduced by about 50% in *taz1Δ* mitochondria using NADH as a respiratory substrate, these mitochondria almost completely failed to phosphorylate ADP when provided with ethanol (Fig. 4A). Obviously, to be effective a stimulation of the Krebs cycle requires a good capacity to transfer electrons to oxygen and this capacity is substantially compromised in our *taz1Δ* yeast owing to a reduced content in several components involved in this transfer (CIII, CIV and cytochrome c). Thus a two-pronged suppressor mechanism leading to an enhanced capacity to reduce NAD^+ and a faster rate of NADH reoxidation is required. In this respect it is to be noted that the functional state of mitochondria influences the expression of numerous nuclear genes through the so-called retrograde pathway as a means to provide the cell with a sufficient supply of metabolites entering the tricarboxylic acid cycle and anabolic reactions, and of proteins involved in oxidative phosphorylation (Jia et al., 1997; Liao and Butow, 1993; Butow and Avadhani, 2004). As we have shown, most of the genes encoding CIII and CIV subunits are strongly down regulated in *fmc1Δ* cells and regained a stronger transcriptional activity when exposed to chlorhexidine, a chemical that substantially improves the ability of these cells to grow on

non-fermentable carbon sources (Couplan et al., 2011). It is possible that changing the flux of Krebs cycle intermediates across the IM in oxidative deficient cells by overexpressing Odc1p secondarily activate the expression of genes encoding subunits of the OXPHOS system, as a means to balance the rates of reduction and re-oxidation of nicotinamide adenine nucleotides.

Our findings make the transport of oxodicarboxylic acids across the IM a potential target for the treatment of BTHS patients and other diseases caused by mitochondrial dysfunction. The rescue of *taz1Δ* (this study) and *fmc1Δ* (Couplan et al., 2011) yeasts by a molecule, oleic acid, known to stimulate Odc1p expression (Tibbetts et al., 2002), holds promise for the discovery of therapeutics targeting this key metabolite carrier.

MATERIAL AND METHODS

Growth media

The following media were used to grow yeast strains, YPAD: 1% (w/v) yeast extract, 2% (w/v) bacto peptone, 60 mg/L adenine and 2% (v/v) glucose; YPE: 1% (w/v) yeast extract, 2% (w/v) bacto peptone, and 2% (v/v) ethanol; CSMGE: 0.17% (w/v) yeast nitrogen base without aminoacids and ammoniumsulfate, 0.5% (w/v) ammonium sulfate, 0.5% (w/v) galactose, 2% ethanol and 0.8% (w/v) of a mixture of aminoacids and bases from Formedium lacking uracil; and WOABDF: 0.17% (w/v) yeast nitrogen base without aminoacids and ammoniumsulfate, 0.5% (w/v) ammonium sulfate, 0.5% (w/v), 2% (v/v) glucose, 50 mg/L adenine, 50 mg/L uracil, 50 mg/L histidine, and 50 mg/L leucine. Solid media contained 2% (w/v) agar.

Construction of *taz1Δ* yeast

taz1Δ yeast was constructed by replacing the open reading frame of *TAZ1* by that of *TRP1* in strain W303-1A (MATa ade2-1 ura3-1 his311, 15 trp1-1 leu2-3,112 can1-100), using a previously described procedure (Longtine et al., 1998). A *taz1::TRP1* DNA cassette was PCR amplified using a plasmid containing *TRP1* (pFA6a-*TRP*), and the primers Taz1-del-F (CAT TTT CAA AAA AAA AAG TAA AGT TTT CCC TAT CAA cgg atc ccc ggg tta att aa) and Taz1-del-R (CCT CAT ACA TGC TAG TAT TTA CAC GAA TTT AAT TGC TTA AAT T gaa ttc gag ctc gtt taa ac). The nucleotides in capital letters correspond *TAZ1* flanking regions, those in lowercase are for *TRP1* amplification. The PCR product was purified before transformation of W303-1A. Transformants were selected on WOABDF plates. The *taz1::TRP1* allele chromosomal integration was PCR verified using a primer internal to *TRP1* (*TRP1*-466-R: CAG TCA GAA ATC GAG TTC CA) and two primers specific for *TAZ1* flanking regions (Taz1-Fbis: CGC CAG GAT CTG ACA GTA T; and Taz1-Rbis: TGA ATT CTA CCA GAT TGG TTA G).

Plasmids

The *TAZ1* gene and its own promoter was PCR amplified from genomic DNA of W303-1A and primers SacI-Taz1-F cccgagctccgCCA TTG TCT CTC CAA TTG GTG and Xho-Taz1-R gcctcgagtcTCA ATC ATC CTT ACC CTT TGG. The SacI and XhoI restriction sites included in the primers were used for cloning the PCR product into vector pRS426 (Mumberg et al., 1994). The plasmid containing *ODC1* (referred in this study as *pODC1*) was described in a previous study in which it is referred to as pLL16 (Schwimmer et al., 2005).

Bioenergetics experiments

Mitochondria were prepared by the enzymatic method as described (Guerin et al., 1979). Protein concentration was determined by the Lowry method (Lowry et al., 1951) in the presence of 5% SDS. Oxygen consumption rates were measured with a Clark electrode using 75 µg/ml of mitochondrial proteins in respiration buffer (0.65 M mannitol, 0.36 mM ethylene glycol tetra-acetic acid, 5 mM Tris-phosphate, 10 mM Tris-maleate, pH 6.8) as in (Rigoulet and Guerin, 1979). The additions were 4 mM NADH, 12.5 mM ascorbate, 1.4 mM N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD), 150 µM ADP, and 4 µM carbonyl cyanide m-chlorophenylhydrazone (CCCP). Variations in transmembrane potential ($\Delta\Psi$) were evaluated in the same respiration buffer by monitoring the quenching of rhodamine 123 fluorescence (0.5 µg/mL) using a FLX Spectrofluorimeter (SAFAS, Monaco), as described in (Emaus et al., 1986). ATP synthesis rate measurements were performed with 75 µg/ml of mitochondrial proteins in respiration buffer supplemented with 4 mM NADH and 1 mM ADP in a thermostatically controlled chamber at 28°C, as described in (Rak et al., 2007b). Aliquots were withdrawn from the oxygraph cuvette every 15 seconds and the reaction was stopped with 3.5% (w/v) perchloric acid, 12.5 mM EDTA. The samples were then neutralized to pH 6.5 by adding 2 M KOH/ 0.3 M MOPS and ATP was quantified using a luciferin/luciferase assay (ATPLite kit from Perkin Elmer) and a LKB bioluminometer. The participation of the F_1F_0 ATP synthase in ATP production was assessed by adding oligomycin (2 µg/ml).

BN-PAGE & SDS-PAGE

Blue native (BN-PAGE) polyacrylamide gel electrophoresis analyses were carried out as described previously (Schagger and von Jagow, 1991). Briefly, mitochondrial extracts solubilized with digitonin (the concentrations used are indicated in the legend of Fig. 5) were separated in a 3–12% acrylamide continuous gradient gel and F_1F_0 complexes were revealed in gel by their ATPase activity as described (Grandier-Vazeille and Guerin, 1996), or by Western blot after transferred to poly(vinylidene difluoride) (Arselin et al., 1996). The complex II activity was revealed in a solution of Tris 5 mM pH 7.4, nitroblue tetrazolium (1 mg/ml), sodium succinate 20 mM and phenazine methosulfate 0.2 mM. SDS-PAGE was performed as described in (Rak et al., 2007b). The sources of antibodies and the dilutions at which they were used are: Atpy- F_1 (J. Velours; 1:10,000), Atp α - F_1 (J. Velours; 1:10,000), cytochrome c (S. Manon; 1:10,000); Taz1 (S. Claypool; 1:5,000); Ade13 (B. Pinson; 1:50,000), Cox2 (Abcam; 1:500), Sdh2 (C. Dallabona; 1:5,000), Cytb (U. Brandt; 1:5,000), Cox4 (Abcam; 1:1,000) and Porin (Molecular Probes; 1:5,000). Nitrocellulose membranes were incubated with 1:2,500 diluted peroxidase-labeled antibodies (Promega).

Immunological signal quantification was performed with ImageJ software (Gassmann et al., 2009).

Phospholipid analysis

Mitochondrial lipids were extracted and analyzed as described (Testet et al., 2005). Briefly, mitochondria were treated with a mixture of chloroform/methanol (2:1, v/v). After centrifugation, the organic phase was separated and the remaining lipids were further extracted twice with chloroform. After the phase separation, the organic phases were pooled and evaporated to dryness. The lipids were then suspended in chloroform/methanol (2:1, v/v). Volumes equivalent to 50 µg of acyl chains were spotted on silica plates. Polar lipids were separated by one dimensional TLC using chloroform/methanol/1-propanol/methylacetate/0.25% KCl (10:4:10:10:3.6, by vol.) as a solvent (Vitiello and Zanetta, 1978). The lipids were then located by immersing the plates in a solution of 0.001% (w/v) primuline in PBS, followed by visualization under UV light. The silica gel zones corresponding to the various lipids (PE, CL, PI and PC) were then scraped from the plates and added to 1 ml of methanol/2.5% H₂SO₄ containing 5 µg of heptadecanoic acid methyl ester as a standard. After maintaining the lipids in the mixture at 80 °C for 1 h, 1.5 ml of water and 400 µl of hexane were added. After centrifugation, hexane phase containing FAMES (fatty acid methyl esters) was isolated. Separation of FAMES was performed as described (Testet et al., 2005).

ROS analyses

0.4 OD of cells were taken from liquid cultures, pelleted in a microcentrifuge, suspended in 1ml of phosphate-buffered saline (PBS) containing 50 µM dihydroethidium (DHE; Molecular Probes) and incubated at room temperature for 5 min. Flow cytometry was carried out on a Becton-Dickinson Accuri C6 model flow cytometer. The DHE fluorescence indicated was the direct output of the FL2A (red fluorescence detecting) channel without compensation. A total of 100,000 cells were analyzed for each curve.

Testing the influence of oleate on *taz1Δ* yeast respiratory growth

0.125 OD of exponentially growing cells were spread homogeneously with sterile glass beads on a square Petri dish (12 cm x 12cm) containing solid YPE medium. Sterile filters were placed on the agar surface and spotted with oleic acid dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mM. The plates were then incubated at 36°C for six days.

ACKNOWLEDGMENTS

This work was supported by the Association Française contre les Myopathies (AFM). MdTdT was supported by a PhD fellowship from the Ministère de l'Enseignement et de la Recherche. We gratefully thank the lipidomic platform of Bordeaux for their lipid analysis on the yeast strains and J.J. Bessoule for helpful discussions.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

AUTHOR CONTRIBUTIONS

D.T.T., J.P.L., MdTdT, and Er.T. performed the experiments; Em.T. helped in BN-PAGE; D.T.T., J.P.L., J.P.dR, MdTdT, and Er.T. analyzed the data; D.T.T., J.P.L., and J.P.dR designed the research and wrote the paper.

LIST OF SYMBOLS AND ABBREVIATIONS

AIR : AminolimidazoleRibotide

BN-PAGE : Blue-NativePolacrylamide-Gel-Electrophoresis

BTHS : Barth syndrome

CIII : Complexes III

CIV : complex IV

CV : Complex V

CCCP : carbonyl cyanide mchlorophenylhydrazone

CL : Cardiolipin

CSM : Complete synthetic medium

$\Delta\Psi$: electrical potential

DHE : Dihydroethidium

DMSO : Dimethyl sulfoxide

ER : endoplasmic reticulum

FAMES : Fatty acid methyl esters

IF1 : natural inhibitory peptide

IM: mitochondrial inner membrane

KCN : Potassium cyanide

mt : Mitochondrial

MLCL : monolyso-CL

OA : Oleic acid

OD_{600nm} : Optical density at 600 nanometer

OXPHOS : oxidative phosphorylation

PA : phosphatidic acid

PBS : Phosphate-buffered saline

PC : Phosphatidylcholine

PE : Phosphatidylethanolamine

PI : Phosphatidylinositol

pØ : Empty plasmid

ρ^- : Large (>50%) deletion of mtDNA

ρ^0 : totally devoid of mtDNA

ρ^+ : functional mtDNA

ROS : reactive oxygen species

taz1Δ : taz1 mutant

TLC : Thin layer chromatography

TMPD : N,N,N',N'-tetramethyl-pphenylenediamine

WT : Wild type

REFERENCES

- Acehan, D., Malhotra, A., Xu, Y., Ren, M., Stokes, D. L. and Schlame, M.** (2011). Cardiolipin affects the supramolecular organization of ATP synthase in mitochondria. *Biophys J* **100**, 2184-92.
- Ades, L. C., Gedeon, A. K., Wilson, M. J., Latham, M., Partington, M. W., Mulley, J. C., Nelson, J., Lui, K. and Sillence, D. O.** (1993). Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28. *Am J Med Genet* **45**, 327-34.
- Arselin, G., Vaillier, J., Graves, P. V. and Velours, J.** (1996). ATP synthase of yeast mitochondria. Isolation of the subunit h and disruption of the ATP14 gene. *J Biol Chem* **271**, 20284-90.
- Baile, M. G. and Claypool, S. M.** (2013). The power of yeast to model diseases of the powerhouse of the cell. *Front Biosci (Landmark Ed)* **18**, 241-78.
- Baile, M. G., Lu, Y. W. and Claypool, S. M.** (2014a). The topology and regulation of cardiolipin biosynthesis and remodeling in yeast. *Chem Phys Lipids* **179**, 25-31.
- Baile, M. G., Sathappa, M., Lu, Y. W., Pryce, E., Whited, K., McCaffery, J. M., Han, X., Alder, N. N. and Claypool, S. M.** (2014b). Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast. *J Biol Chem* **289**, 1768-78.
- Ban, T., Heymann, J. A., Song, Z., Hinshaw, J. E. and Chan, D. C.** (2010). OPA1 disease alleles causing dominant optic atrophy have defects in cardiolipin-stimulated GTP hydrolysis and membrane tubulation. *Hum Mol Genet* **19**, 2113-22.
- Barth, P. G., Scholte, H. R., Berden, J. A., Van der Klei-Van Moorsel, J. M., Luyt-Houwen, I. E., Van 't Veer-Korthof, E. T., Van der Harten, J. J. and Sobotka-Plojhar, M. A.** (1983). An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. *J Neurol Sci* **62**, 327-55.
- Barth, P. G., Valianpour, F., Bowen, V. M., Lam, J., Duran, M., Vaz, F. M. and Wanders, R. J.** (2004). X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. *Am J Med Genet A* **126A**, 349-54.
- Barth, P. G., Van den Bogert, C., Bolhuis, P. A., Scholte, H. R., van Gennip, A. H., Schutgens, R. B. and Ketel, A. G.** (1996). X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory-chain abnormalities in cultured fibroblasts. *J Inherit Metab Dis* **19**, 157-60.
- Bazan, S., Mileykovskaya, E., Mallampalli, V. K., Heacock, P., Sparagna, G. C. and Dowhan, W.** (2013). Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified *Saccharomyces cerevisiae* complexes III and IV. *J Biol Chem* **288**, 401-11.
- Bione, S., D'Adamo, P., Maestrini, E., Gedeon, A. K., Bolhuis, P. A. and Toniolo, D.** (1996). A novel X-linked gene, G4.5. is responsible for Barth syndrome. *Nat Genet* **12**, 385-9.
- Bligny, R. and Douce, R.** (1980). A precise localization of cardiolipin in plant cells. *Biochim Biophys Acta* **617**, 254-63.
- Bolhuis, P. A., Hensels, G. W., Hulsebos, T. J., Baas, F. and Barth, P. G.** (1991). Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. *Am J Hum Genet* **48**, 481-5.

Brandner, K., Mick, D. U., Frazier, A. E., Taylor, R. D., Meisinger, C. and Rehling, P. (2005). Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome. *Mol Biol Cell* **16**, 5202-14.

Butow, R. A. and Avadhani, N. G. (2004). Mitochondrial signaling: the retrograde response. *Mol Cell* **14**, 1-15.

Chen, S., He, Q. and Greenberg, M. L. (2008). Loss of tafazzin in yeast leads to increased oxidative stress during respiratory growth. *Mol Microbiol* **68**, 1061-72.

Chen, X. J. and Clark-Walker, G. D. (2000). The petite mutation in yeasts: 50 years on. *Int Rev Cytol* **194**, 197-238.

Chu, C. T., Bayir, H. and Kagan, V. E. (2014). LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons: implications for Parkinson disease. *Autophagy* **10**, 376-8.

Chu, C. T., Ji, J., Dagda, R. K., Jiang, J. F., Tyurina, Y. Y., Kapralov, A. A., Tyurin, V. A., Yanamala, N., Shrivastava, I. H., Mohammadyani, D. et al. (2013). Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. *Nat Cell Biol* **15**, 1197-205.

Claypool, S. M. (2009). Cardiolipin, a critical determinant of mitochondrial carrier protein assembly and function. *Biochim Biophys Acta* **1788**, 2059-68.

Claypool, S. M., Boontheung, P., McCaffery, J. M., Loo, J. A. and Koehler, C. M. (2008). The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome. *Mol Biol Cell* **19**, 5143-55.

Claypool, S. M., McCaffery, J. M. and Koehler, C. M. (2006). Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins. *J Cell Biol* **174**, 379-90.

Claypool, S. M., Whited, K., Srijumnong, S., Han, X. and Koehler, C. M. (2011). Barth syndrome mutations that cause tafazzin complex lability. *J Cell Biol* **192**, 447-62.

Contamine, V. and Picard, M. (2000). Maintenance and integrity of the mitochondrial genome: a plethora of nuclear genes in the budding yeast. *Microbiol Mol Biol Rev* **64**, 281-315.

Couplan, E., Aiyar, R. S., Kucharczyk, R., Kabala, A., Ezkurdia, N., Gagneur, J., St Onge, R. P., Salin, B., Soubigou, F., Le Cann, M. et al. (2011). A yeast-based assay identifies drugs active against human mitochondrial disorders. *Proc Natl Acad Sci U S A* **108**, 11989-94.

Dallabona, C., Marsano, R. M., Arzuffi, P., Ghezzi, D., Mancini, P., Zeviani, M., Ferrero, I. and Donnini, C. (2010). Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator. *Hum Mol Genet* **19**, 1098-107.

DeVay, R. M., Dominguez-Ramirez, L., Lackner, L. L., Hoppins, S., Stahlberg, H. and Nunnari, J. (2009). Coassembly of Mgm1 isoforms requires cardiolipin and mediates mitochondrial inner membrane fusion. *J Cell Biol* **186**, 793-803.

Dudek, J., Cheng, I. F., Balleininger, M., Vaz, F. M., Streckfuss-Bomeke, K., Hubscher, D., Vukotic, M., Wanders, R. J., Rehling, P. and Guan, K. (2013). Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome. *Stem Cell Res* **11**, 806-19.

Dudek, J., Cheng, I. F., Chowdhury, A., Wozny, K., Balleininger, M., Reinhold, R., Grunau, S., Callegari, S., Toischer, K., Wanders, R. J. et al. (2016). Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome. *EMBO Mol Med* **8**, 139-54.

Emaus, R. K., Grunwald, R. and Lemasters, J. J. (1986). Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. *Biochim Biophys Acta* **850**, 436-48.

Ferri, L., Donati, M. A., Funghini, S., Malvagia, S., Catarzi, S., Lugli, L., Ragni, L., Bertini, E., Vaz, F. M., Cooper, D. N. et al. (2013). New clinical and molecular insights on Barth syndrome. *Orphanet J Rare Dis* **8**, 27.

Fiermonte, G., Dolce, V., Palmieri, L., Ventura, M., Runswick, M. J., Palmieri, F. and Walker, J. E. (2001). Identification of the human mitochondrial oxodicarboxylate carrier. Bacterial expression, reconstitution, functional characterization, tissue distribution, and chromosomal location. *J Biol Chem* **276**, 8225-30.

Francisci, S., Montanari, A., De Luca, C. and Frontali, L. (2011). Peptides from aminoacyl-tRNA synthetases can cure the defects due to mutations in mt tRNA genes. *Mitochondrion* **11**, 919-23.

Gassmann, M., Grenacher, B., Rohde, B. and Vogel, J. (2009). Quantifying Western blots: pitfalls of densitometry. *Electrophoresis* **30**, 1845-55.

Gebert, N., Joshi, A. S., Kutik, S., Becker, T., McKenzie, M., Guan, X. L., Mooga, V. P., Stroud, D. A., Kulkarni, G., Wenk, M. R. et al. (2009). Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome. *Curr Biol* **19**, 2133-9.

Gedeon, A. K., Wilson, M. J., Colley, A. C., Sillence, D. O. and Mulley, J. C. (1995). X linked fatal infantile cardiomyopathy maps to Xq28 and is possibly allelic to Barth syndrome. *J Med Genet* **32**, 383-8.

Gonzalez, F., D'Aurelio, M., Boutant, M., Moustapha, A., Puech, J. P., Landes, T., Arnaune-Pelloquin, L., Vial, G., Taleux, N., Slomianny, C. et al. (2013). Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation. *Biochim Biophys Acta* **1832**, 1194-206.

Gonzalez, F. and Gottlieb, E. (2007). Cardiolipin: setting the beat of apoptosis. *Apoptosis* **12**, 877-85.

Grandier-Vazeille, X. and Guerin, M. (1996). Separation by blue native and colorless native polyacrylamide gel electrophoresis of the oxidative phosphorylation complexes of yeast mitochondria solubilized by different detergents: specific staining of the different complexes. *Anal Biochem* **242**, 248-54.

Gu, Z., Valianpour, F., Chen, S., Vaz, F. M., Hakkaart, G. A., Wanders, R. J. and Greenberg, M. L. (2004). Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome. *Mol Microbiol* **51**, 149-58.

Guerin, B., Labbe, P. and Somlo, M. (1979). Preparation of yeast mitochondria (*Saccharomyces cerevisiae*) with good P/O and respiratory control ratios. *Methods Enzymol* **55**, 149-59.

Hatch, G. M. (1998). Cardiolipin: biosynthesis, remodeling and trafficking in the heart and mammalian cells (Review). *Int J Mol Med* **1**, 33-41.

Heit, B., Yeung, T. and Grinstein, S. (2011). Changes in mitochondrial surface charge mediate recruitment of signaling molecules during apoptosis. *Am J Physiol Cell Physiol* **300**, C33-41.

Hoch, F. L. (1992). Cardiolipins and biomembrane function. *Biochim Biophys Acta* **1113**, 71-133.

Hostetler, K. Y., van den Bosch, H. and van Deenen, L. L. (1972). The mechanism of cardiolipin biosynthesis in liver mitochondria. *Biochim Biophys Acta* **260**, 507-13.

Hsu, P., Liu, X., Zhang, J., Wang, H. G., Ye, J. M. and Shi, Y. (2015). Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy. *Autophagy* **11**, 643-52.

Ikon, N., Su, B., Hsu, F. F., Forte, T. M. and Ryan, R. O. (2015). Exogenous cardiolipin localizes to mitochondria and prevents TAZ knockdown-induced apoptosis in myeloid progenitor cells. *Biochem Biophys Res Commun* **464**, 580-5.

Jia, Y., Rothermel, B., Thornton, J. and Butow, R. A. (1997). A basic helix-loop-helix-leucine zipper transcription complex in yeast functions in a signaling pathway from mitochondria to the nucleus. *Mol Cell Biol* **17**, 1110-7.

Jiang, F., Ryan, M. T., Schlame, M., Zhao, M., Gu, Z., Klingenberg, M., Pfanner, N. and Greenberg, M. L. (2000). Absence of cardiolipin in the *crd1* null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. *J Biol Chem* **275**, 22387-94.

Joshi, A. S., Thompson, M. N., Fei, N., Huttemann, M. and Greenberg, M. L. (2012). Cardiolipin and mitochondrial phosphatidylethanolamine have overlapping functions in mitochondrial fusion in *Saccharomyces cerevisiae*. *J Biol Chem* **287**, 17589-97.

Joshi, A. S., Zhou, J., Gohil, V. M., Chen, S. and Greenberg, M. L. (2009). Cellular functions of cardiolipin in yeast. *Biochim Biophys Acta* **1793**, 212-8.

Kadenbach, B., Mende, P., Kolbe, H. V., Stipani, I. and Palmieri, F. (1982). The mitochondrial phosphate carrier has an essential requirement for cardiolipin. *FEBS Lett* **139**, 109-12.

Kim, G., Sikder, H. and Singh, K. K. (2002). A colony color method identifies the vulnerability of mitochondria to oxidative damage. *Mutagenesis* **17**, 375-81.

Kim, T. H., Zhao, Y., Ding, W. X., Shin, J. N., He, X., Seo, Y. W., Chen, J., Rabinowich, H., Amoscato, A. A. and Yin, X. M. (2004). Bid-cardiolipin interaction at mitochondrial contact site contributes to mitochondrial cristae reorganization and cytochrome C release. *Mol Biol Cell* **15**, 3061-72.

Koshkin, V. and Greenberg, M. L. (2000). Oxidative phosphorylation in cardiolipin-lacking yeast mitochondria. *Biochem J* **347 Pt 3**, 687-91.

Koshkin, V. and Greenberg, M. L. (2002). Cardiolipin prevents rate-dependent uncoupling and provides osmotic stability in yeast mitochondria. *Biochem J* **364**, 317-22.

Kucharczyk, R., Salin, B. and di Rago, J. P. (2009). Introducing the human Leigh syndrome mutation T9176G into *Saccharomyces cerevisiae* mitochondrial DNA leads to severe defects in the incorporation of Atp6p into the ATP synthase and in the mitochondrial morphology. *Hum Mol Genet* **18**, 2889-98.

Lasserre, J. P., Dautant, A., Aiyar, R. S., Kucharczyk, R., Glatigny, A., Tribouillard-Tanvier, D., Rytka, J., Blondel, M., Skoczen, N., Reynier, P. et al. (2015). Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies. *Dis Model Mech* **8**, 509-526.

Lefebvre-Legendre, L., Balguerie, A., Duvezin-Caubet, S., Giraud, M. F., Slonimski, P. P. and Di Rago, J. P. (2003). F1-catalysed ATP hydrolysis is required for mitochondrial biogenesis in *Saccharomyces cerevisiae* growing under conditions where it cannot respire. *Mol Microbiol* **47**, 1329-39.

Li, X. X., Tsoi, B., Li, Y. F., Kurihara, H. and He, R. R. (2015). Cardiolipin and its different properties in mitophagy and apoptosis. *J Histochem Cytochem* **63**, 301-11.

Liao, X. and Butow, R. A. (1993). RTG1 and RTG2: two yeast genes required for a novel path of communication from mitochondria to the nucleus. *Cell* **72**, 61-71.

Longtine, M. S., McKenzie, A., 3rd, Demarini, D. J., Shah, N. G., Wach, A., Brachat, A., Philippsen, P. and Pringle, J. R. (1998). Additional modules for versatile and economical PCR-based gene deletion and modification in *Saccharomyces cerevisiae*. *Yeast* **14**, 953-61.

Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**, 265-75.

Manganelli, V., Capozzi, A., Recalchi, S., Signore, M., Mattei, V., Garofalo, T., Misasi, R., Degli Esposti, M. and Sorice, M. (2015). Altered Traffic of Cardiolipin during Apoptosis: Exposure on the Cell Surface as a Trigger for "Antiphospholipid Antibodies". *J Immunol Res* **2015**, 847985.

McKenzie, M., Lazarou, M., Thorburn, D. R. and Ryan, M. T. (2006). Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. *J Mol Biol* **361**, 462-9.

McMillin, J. B. and Dowhan, W. (2002). Cardiolipin and apoptosis. *Biochim Biophys Acta* **1585**, 97-107.

Mileyskovskaya, E. and Dowhan, W. (2014). Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes. *Chem Phys Lipids* **179**, 42-8.

Montanari, A., Besagni, C., De Luca, C., Morea, V., Oliva, R., Tramontano, A., Bolotin-Fukuhara, M., Frontali, L. and Francisci, S. (2008). Yeast as a model of human mitochondrial tRNA base substitutions: investigation of the molecular basis of respiratory defects. *RNA* **14**, 275-83.

Montanari, A., De Luca, C., Frontali, L. and Francisci, S. (2010). Aminoacyl-tRNA synthetases are multivalent suppressors of defects due to human equivalent mutations in yeast mt tRNA genes. *Biochim Biophys Acta* **1803**, 1050-7.

Mumberg, D., Muller, R. and Funk, M. (1994). Regulatable promoters of *Saccharomyces cerevisiae*: comparison of transcriptional activity and their use for heterologous expression. *Nucleic Acids Res* **22**, 5767-8.

Neuwald, A. F. (1997). Barth syndrome may be due to an acyltransferase deficiency. *Curr Biol* **7**, R465-6.

Noel, H. and Pande, S. V. (1986). An essential requirement of cardiolipin for mitochondrial carnitine acylcarnitine translocase activity. Lipid requirement of carnitine acylcarnitine translocase. *Eur J Biochem* **155**, 99-102.

Orrenius, S. and Zhivotovsky, B. (2005). Cardiolipin oxidation sets cytochrome c free. *Nat Chem Biol* **1**, 188-9.

Park, H., Davidson, E. and King, M. P. (2008). Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. *RNA* **14**, 2407-16.

Patil, V. A., Fox, J. L., Gohil, V. M., Winge, D. R. and Greenberg, M. L. (2013). Loss of cardiolipin leads to perturbation of mitochondrial and cellular iron homeostasis. *J Biol Chem* **288**, 1696-705.

Pfeiffer, K., Gohil, V., Stuart, R. A., Hunte, C., Brandt, U., Greenberg, M. L. and Schagger, H. (2003). Cardiolipin stabilizes respiratory chain supercomplexes. *J Biol Chem* **278**, 52873-80.

Rak, M., Tetaud, E., Duvezin-Caubet, S., Ezkurdia, N., Bietenhader, M., Rytka, J. and di Rago, J. P. (2007a). A yeast model of the neurogenic ataxia retinitis pigmentosa (NARP) T8993G mutation in the mitochondrial ATP synthase-6 gene. *J Biol Chem* **282**, 34039-47.

Rak, M., Tetaud, E., Godard, F., Sagot, I., Salin, B., Duvezin-Caubet, S., Slonimski, P. P., Rytka, J. and di Rago, J. P. (2007b). Yeast cells lacking the mitochondrial gene encoding the ATP synthase subunit 6 exhibit a selective loss of complex IV and unusual mitochondrial morphology. *J Biol Chem* **282**, 10853-64.

Reaume, S. E. and Tatum, E. L. (1949). Spontaneous and nitrogen mustard-induced nutritional deficiencies in *Saccharomyces cerevisiae*. *Arch Biochem* **22**, 331-8.

Rigoulet, M. and Guerin, B. (1979). Phosphate transport and ATP synthesis in yeast mitochondria: effect of a new inhibitor: the tribenzylphosphate. *FEBS Lett* **102**, 18-22.

Rigoulet, M., Velours, J. and Guerin, B. (1985). Substrate-level phosphorylation in isolated yeast mitochondria. *Eur J Biochem* **153**, 601-7.

Robinson, N. C. (1993). Functional binding of cardiolipin to cytochrome c oxidase. *J Bioenerg Biomembr* **25**, 153-63.

Rorbach, J., Yusoff, A. A., Tuppen, H., Abg-Kamaludin, D. P., Chrzanowska-Lightowlers, Z. M., Taylor, R. W., Turnbull, D. M., McFarland, R. and Lightowlers, R. N. (2008). Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNA^{Val} carrying the pathogenic C25U mutation. *Nucleic Acids Res* **36**, 3065-74.

Sasarman, F., Antonicka, H. and Shoubbridge, E. A. (2008). The A3243G tRNA^{Leu}(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. *Hum Mol Genet* **17**, 3697-707.

Sauerwald, J., Jores, T., Eisenberg-Bord, M., Chuartzman, S. G., Schuldiner, M. and Rapaport, D. (2015). Genome-Wide Screens in *Saccharomyces cerevisiae* Highlight a Role for Cardiolipin in Biogenesis of Mitochondrial Outer Membrane Multispan Proteins. *Mol Cell Biol* **35**, 3200-11.

Schagger, H. and von Jagow, G. (1991). Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. *Anal Biochem* **199**, 223-31.

Schlame, M. (2013). Cardiolipin remodeling and the function of tafazzin. *Biochim Biophys Acta* **1831**, 582-8.

Schlame, M., Acehan, D., Berno, B., Xu, Y., Valvo, S., Ren, M., Stokes, D. L. and Epand, R. M. (2012). The physical state of lipid substrates provides transacylation specificity for tafazzin. *Nat Chem Biol* **8**, 862-9.

Schlame, M. and Haldar, D. (1993). Cardiolipin is synthesized on the matrix side of the inner membrane in rat liver mitochondria. *J Biol Chem* **268**, 74-9.

Schlame, M., Kelley, R. I., Feigenbaum, A., Towbin, J. A., Heerdt, P. M., Schieble, T., Wanders, R. J., DiMauro, S. and Blanck, T. J. (2003). Phospholipid abnormalities in children with Barth syndrome. *J Am Coll Cardiol* **42**, 1994-9.

Schlame, M., Rua, D. and Greenberg, M. L. (2000). The biosynthesis and functional role of cardiolipin. *Prog Lipid Res* **39**, 257-88.

Schwimmer, C., Lefebvre-Legendre, L., Rak, M., Devin, A., Slonimski, P. P., di Rago, J. P. and Rigoulet, M. (2005). Increasing mitochondrial substrate-level phosphorylation can rescue respiratory growth of an ATP synthase-deficient yeast. *J Biol Chem* **280**, 30751-9.

Spinazzola, A., Viscomi, C., Fernandez-Vizarra, E., Carrara, F., D'Adamo, P., Calvo, S., Marsano, R. M., Donnini, C., Weiher, H., Strisciuglio, P. et al. (2006). MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. *Nat Genet* **38**, 570-5.

Testet, E., Laroche-Traineau, J., Noubhani, A., Coulon, D., Bunoust, O., Camougrand, N., Manon, S., Lessire, R. and Bessoule, J. J. (2005). Ypr140wp, 'the yeast tafazzin', displays a mitochondrial lysophosphatidylcholine (lyso-PC) acyltransferase activity related to triacylglycerol and mitochondrial lipid synthesis. *Biochem J* **387**, 617-26.

Tibbetts, A. S., Sun, Y., Lyon, N. A., Ghrist, A. C. and Trotter, P. J. (2002). Yeast mitochondrial oxodicarboxylate transporters are important for growth on oleic acid. *Arch Biochem Biophys* **406**, 96-104.

Valianpour, F., Mitsakos, V., Schlemmer, D., Towbin, J. A., Taylor, J. M., Ekert, P. G., Thorburn, D. R., Munnich, A., Wanders, R. J., Barth, P. G. et al. (2005). Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis. *J Lipid Res* **46**, 1182-95.

Vaz, F. M., Houtkooper, R. H., Valianpour, F., Barth, P. G. and Wanders, R. J. (2003). Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism. *J Biol Chem* **278**, 43089-94.

Venard, R., Brethes, D., Giraud, M. F., Vaillier, J., Velours, J. and Haraux, F. (2003). Investigation of the role and mechanism of IF1 and STF1 proteins, twin inhibitory peptides which interact with the yeast mitochondrial ATP synthase. *Biochemistry* **42**, 7626-36.

Vitiello, F. and Zanetta, J. P. (1978). Thin-layer chromatography of phospholipids. *J Chromatogr* **166**, 637-40.

Vreken, P., Valianpour, F., Nijtmans, L. G., Grivell, L. A., Plecko, B., Wanders, R. J. and Barth, P. G. (2000). Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. *Biochem Biophys Res Commun* **279**, 378-82.

Wittig, I. and Schagger, H. (2009). Supramolecular organization of ATP synthase and respiratory chain in mitochondrial membranes. *Biochim Biophys Acta* **1787**, 672-80.

Xu, Y., Condell, M., Plesken, H., Edelman-Novemsky, I., Ma, J., Ren, M. and Schlame, M. (2006). A Drosophila model of Barth syndrome. *Proc Natl Acad Sci U S A* **103**, 11584-8.

Xu, Y., Sutachan, J. J., Plesken, H., Kelley, R. I. and Schlame, M. (2005). Characterization of lymphoblast mitochondria from patients with Barth syndrome. *Lab Invest* **85**, 823-30.

Zhang, M., Mileykovskaya, E. and Dowhan, W. (2002). Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. *J Biol Chem* **277**, 43553-6.

Figures






Figure 1. Overexpressing Odc1p does not restore a normal phospholipid profile in *taz1Δ* yeast mitochondria. (A) Steady-state levels of Odc1p and Taz1p. Total protein extracts were prepared from cells of the four analyzed strains (WT + pØ; *taz1Δ* + pØ, *taz1Δ* + pTAZ1; *taz1Δ* + pODC1) grown at 36°C in a complete synthetic media containing galactose and ethanol (see Fig. 2B for details). The proteins were separated by SDS-PAGE, transferred onto a nitrocellulose membrane and probed with antibodies against Odc1p and Taz1p, and the cytosolic Ade13p protein that was used as a loading control. 50µg of proteins were loaded on each lane. The arrow points to Odc1p. **(B)** Phospholipid composition and fatty acid chains in cardiolipin. Mitochondria were prepared from the analyzed strains grown as in panel A (see also Fig. 2B), and their lipids extracted and quantified (see experimental section). The upper panel shows the relative contents in % within each strain of PE (phosphatidylethanolamine), CL (cardiolipin), PI (phosphatidylinositol) and PC (phosphatidylcholine). The bottom panel gives the relative fatty acid chain composition of CL within each strain (16:0, palmitic acid; 16:1, palmitoleic acid; 18:0, stearic acid; 18:1: oleic acid). Statistical analysis has been done with Kruskal-Wallis test (*p < 0.05; **p < 0.01; ***p < 0.001). Data are expressed as mean ± SD (n=4).

A



B



C




Figure 2. Growth properties and genetic stability of yeast strains. (A) Growth on glucose and ethanol. Cells from the four analyzed strain (WT + pØ; *taz1Δ* + pØ, *taz1Δ* + pTAZ1; *taz1Δ* + pODC1) freshly grown at 28°C in complete synthetic media (CSM) containing 2% glucose as a carbon source were serially diluted and spotted onto solid CSM + 2% ethanol or CSM + 2% glucose plates. The plates were photographed after 4 days of incubation at the indicated temperature. **(B)** Growth curves. Cells from the analyzed strains freshly grown in CSM+ 2% glucose at 28°C were inoculated into 50 ml of CSM + 0.5% galactose + 2% ethanol, and incubated at 36°C with shaking. Optical densities were measured over time during one week. The bioenergetics and biochemical investigations described in Figs. 3-5 were performed with cells grown in these conditions (in 2 L. of medium) until 2-3 OD_{600 nm}/ml as indicated by the arrow pointing to 'Mito prep'. **(C)** Production of ρ^-/ρ^0 cells. Subclones of *WT* and *taz1Δ* mutant strains were grown on solid glucose plates with a limiting amount of adenine. Clones with a red color were picked-up and streaked on the same media. The plates were photographed after 6 days of incubation at 28°C. As explained in the text, ρ^-/ρ^0 form entirely white colonies while those predominantly made of ρ^+ cells are red.




A**B****C**

Figure 3. Respiration and ATP synthesis in isolated mitochondria. (A-B) Oxygen consumption. The rates of oxygen consumption in panel A were measured using NADH as an electron donor, alone (NADH, state 4), after further addition of ADP (NADH+ADP, state 3) or CCCP (NADH + CCCP, uncoupled respiration); those shown in panel B were measured using ascorbate/TMPD as an electron source in the presence of CCCP (Asc/TMPD + CCCP). **(C)** ATP synthesis. The rates of ATP synthesis were measured using NADH as a respiratory substrate and in the presence of a large excess of external ADP. All experiments were done 4 times. Are reported the mean values expressed in % of those obtained for the control (WT + pØ) with their standard deviations (represented by the bars). The mitochondria were prepared from cells grown as described in Fig. 2B. Statistical analysis has been done with Turkey's test (*p < 0.05; **p < 0.01; ***p < 0.001). Data are expressed as mean ± SD (n=4).




Figure 4. Mitochondrial membrane potential. Variations in mitochondrial $\Delta\Psi$ were monitored by the fluorescence quenching of rhodamine 123 (see material and methods section). The additions were 0.5 $\mu\text{g/ml}$ Rhodamine 123, 75 $\mu\text{g/ml}$ mitochondrial proteins (Mito), 10 μl of ethanol (EtOH), 0.2 mM potassium cyanide (KCN), 50 μM ADP, 3 μM CCCP, 1 mM ATP, and 6 mg/ml oligomycin (oligo). The shown fluorescence traces are representative of four experimental trials. The mitochondria used in these experiments were prepared from cells grown as described in Fig. 2B.




Figure 5. BN- and SDS-PAGE analyses of mitochondrial proteins. The shown experiments were performed with mitochondria isolated from strains WT + pØ, *taz1Δ* + pØ, *taz1Δ* + pTAZ1 and *taz1Δ* + pODC1 grown as described in Fig. 2B. **(A)** BN-PAGE analyses of ATP synthase. The left panel shows a BN-gel of mitochondrial proteins (50 µg) dissolved with 2 g of digitonin per g of proteins, where ATP synthase is revealed by its ATPase activity

as dimers (V₂), monomers (V₁) or free F₁ particles (F₁). In the right panel, ATP synthase was analyzed in samples (50 µg) obtained after treating the mitochondria with increasing concentrations of digitonin, from 0.5 to 3.0 g per g of proteins. After their electrophoretic separation and transfer onto a nitrocellulose membrane, the proteins were probed with antibodies against the γ-F₁ subunit (Atp3p) of ATP synthase. **(B)** BN-PAGE analysis of CIV and CIII. Mitochondrial proteins were extracted with 10 g of digitonin per g of proteins, separated by BN-PAGE (100 µg per lane), transferred onto a nitrocellulose membrane, and probed with antibodies against the Cox2 subunit of CIV or the Cytb subunit of CIII. **(C)** BN-PAGE and SDS-PAGE analyses of CII. On the left panel, mitochondrial proteins were extracted with digitonin (10g/g), separated by BN-PAGE, and assayed for in-gel complex II activity; on the right panel, 100 µg of total protein extracts were separated by SDS-PAGE, transferred onto a nitrocellulose membrane and probed antibodies against Sdh2 and Ade13. **(D)** SDS-PAGE analyses. 100 µg of total mitochondrial proteins were separated by SDS-PAGE, transferred onto a nitrocellulose membrane and probed antibodies against the indicated proteins. The right panel shows a quantification which as been done using the ImageJ software. The levels of Cox2, Atpα-F₁ and Cyt c have been related to the mitochondrial protein Por1. The data are all relative to *WT*.




Figure 6. ROS levels in yeast cells. The four analyzed strains (WT + pØ; *taz1Δ* + pØ, *taz1Δ* + pTAZ1; *taz1Δ* + pODC1) were grown as depicted in Fig. 2B. Cell samples were taken at the indicated times and analyzed by flow cytometry using dihydroethidium as a probe. The experiment was repeated three times for each strain. The average values and their standard deviation (error bars) are indicated. Statistical analysis has been done with Turkey's test (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$). Data are expressed as mean \pm SD (n=3).




Figure 7. Oleic acid improves respiratory growth of *taz1Δ* yeast. Cells of *taz1Δ* yeast freshly grown in glucose were spread onto rich media with or without ethanol as a carbon source. Small sterile filters were then placed on the medium and oleate (dissolved in DMSO) or DMSO alone were added to the filters at the indicated quantities. The plates were photographed after 5 days of incubation at 36°C.